Take a look at some of the events in regulatory intelligence with pharma and biotech this week!
- Regeneron, together with Intouch Solutions, has developed and launched a virtual and augmented reality app to allow people to “see” what it’s like to have retinal disease. The app, called “In My Eyes” was originally meant as a sales tool and includes branding for Eylea, but expanded to be used for education with caregivers, patients, and their family and friends. (FiercePharma)
- Kite Pharma’s CAR T-cell therapy meets study goal, stating it was shown to be highly effective in the treatment of aggressive non-Hodgkin’s lymphoma. (Reuters)
- FDA granted Teva Pharmaceutical Industries priority review for its experimental therapy, SD-809, to treat tardive dyskinesia. Tardive dyskinesia is a disorder marked by uncontrollable movements for which there are no currently approved therapies. (Reuters)
- The FDA approved AstraZeneca’s Qtern, a combination of dapagliflozin and saxagliptin, as a supplement to diet and exercise, for the improvement of glycemic control in adults with type-2 diabetes. (Pharmafile)
- Roche initiates phase 3 trial in Alzheimer’s disease. Despite failures from similar drugs, Roche announced that the company has begun a second late-stage trial of crenezumab, in partnership with the Swiss biotech company AC immune, the developer of the drug. (Reuters)